QC
RLAY icon

Quadrature Capital’s Relay Therapeutics RLAY Stock Holding History

Quadrature Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,123
Closed -$210K – 1980
2026
Q1 		$210K Buy
+21,123
New +$189K ﹤0.01% 1104
2025
Q3 		– Sell
-13,496
Closed -$46.8K – 1427
2025
Q2 		$46.8K Buy
+13,496
New +$40.1K ﹤0.01% 953

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Quadrature Capital's RLAY Position: Q2 2026 in Review

Quadrature Capital sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 21,123 shares — an estimated $210K sold.

Quadrature Capital first reported a position in RLAY in Q2 2025 and held it in 2 quarters. The position peaked at $210K in Q1 2026. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Quadrature Capital reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 21,123 Relay Therapeutics shares in Q2 2026, an estimated $210K.
  • Quadrature Capital first reported a position in Relay Therapeutics in Q2 2025 and held it in 2 quarters.
  • Quadrature Capital's Relay Therapeutics position peaked at $210K in Q1 2026.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.